PHF6 functions as a tumor suppressor by recruiting methyltransferase SUV39H1 to nucleolar region and offers a novel therapeutic target for PHF6-muntant leukemia

Tsai, Hsiang‐i; Wu, Yanping; Huang, Rui; Su, Dandan; Wu, Yingyi; Liu, Xiaoyan; Wang, Linglu; Xu, Zhanxue; Pang, Yuxin; Sun, Chong; He, Chao; Shu, Fan; Zhu, Haitao; Wang, Dongqing; Cheng, Fang; Huang, Laiqiang; Chen, Hongbo

doi:10.1016/j.apsb.2021.10.025

Search citation statements

Order By: Relevance

Paper Sections

Select...

Females Express a Higher Dosage Of X-linked Tumour Suppresso...1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2023

2024

Publication Types

Select...

Article4

Other1

Relationship

Self Cite0

Independent5

Authors

Journals

Cited by 6 publications

(1 citation statement)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Surprisingly, we found PHF6 to be expressed from only one allele (monoallelic) (Figure 22D). PHF6 has been extensively studied as a driver of T-ALL progression [436][437][438] and was found to be mutated almost exclusively in male T-ALL patients [439]. As only one allele of PHF6 is expressed in all thymocyte subpopulations in males and females, any loss of function mutation in this gene should be equally detrimental in both sexes.…”

Section: Females Express a Higher Dosage Of X-linked Tumour Suppresso...mentioning

confidence: 99%

DNA methylation in T cell leukaemia

Bensberg

2024

Linköping University Medical Dissertations

View full text Add to dashboard Cite

show abstract

Section: Females Express a Higher Dosage Of X-linked Tumour Suppresso...mentioning

confidence: 99%

DNA methylation in T cell leukaemia

Bensberg

2024

Linköping University Medical Dissertations

View full text Add to dashboard Cite

show abstract

Epigenetic regulation in cancer therapy: From mechanisms to clinical advances

Tao,

Zhou,

Luo

et al. 2024

MedComm – Oncology

View full text Add to dashboard Cite

Epigenetic regulation refers to the alteration of gene expression independent of changes in DNA sequence. It involves chemical modifications such as DNA methylation, histone methylation, and histone acetylation, which are regulated by a coordinated interplay of various regulators to ensure precise spatial and temporal regulation of gene expression. Epigenetic aberrations are commonly observed in cancer and are considered as hallmarks of cancer. In recent years, small molecules targeting specific epigenetic regulators have been developed and are demonstrating promising therapeutic potential in preclinical and clinical trials for cancer treatment. In this review, we summarize the essential regulatory mechanisms and dysfunctions of epigenetic regulators involved in DNA methylation, histone methylation, and histone acetylation during tumor development and progression. Moreover, we discuss the current advances and challenges in cancer epigenetic therapy that target these mechanisms in both hematologic malignancies and solid tumors. Finally, we discuss the potential of combining epigenetic drugs with other therapies, including chemotherapy, radiotherapy, targeted therapy, and immunotherapy, as a promising approach for cancer treatment. Overall, we aim to enhance the understanding of epigenetic regulation in cancer therapy and explore targeted therapeutic strategies based on these mechanisms, to ultimately advance cancer therapy and improve patient prognosis.

show abstract

Hydrolytic Metabolism of Withangulatin A Mediated by Serum Albumin Instead of Common Esterases in Plasma

Zhuang,

Wang,

et al. 2023

Eur J Drug Metab Pharmacokinet

View full text Add to dashboard Cite

PHF6 functions as a tumor suppressor by recruiting methyltransferase SUV39H1 to nucleolar region and offers a novel therapeutic target for PHF6-muntant leukemia

Cited by 6 publications

References 34 publications

DNA methylation in T cell leukaemia

DNA methylation in T cell leukaemia

Epigenetic regulation in cancer therapy: From mechanisms to clinical advances

Hydrolytic Metabolism of Withangulatin A Mediated by Serum Albumin Instead of Common Esterases in Plasma

Contact Info

Product

Resources

About